Skip to main content
Swing Capital

Gufic BioSciences Ltd

NSE: GUFICBIO BSE: 509079

Gufic Biosciences Limited is engaged in the manufacture of pharmaceuticals, medicinal chemicals and botanical products.

₹275
52W: ₹268 — ₹409
PE 54.6 · Book ₹62.7 · +339% vs book
Market Cap₹2,758 Cr
Stock P/E54.6Price to Earnings
ROCE13.2%Return on Capital
ROE12.3%Return on Equity
Div. Yield0.04%Face Value ₹1

Strengths

  • +Company's median sales growth is 19.4% of last 10 years

Weaknesses

  • −Company might be capitalizing the interest cost

Shareholding Pattern

Promoters72.5%
FIIs0.42%
DIIs3.83%
Public23.23%
CategoryJun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Promoters72.51%72.51%72.51%72.51%72.51%72.5%▼0.072.5%72.5%
FIIs0.23%0.23%0.3%▲0.10.31%▲0.00.32%▲0.00.33%▲0.00.44%▲0.10.42%▼0.0
DIIs2.38%2.51%▲0.12.99%▲0.53.39%▲0.43.38%▼0.03.66%▲0.33.74%▲0.13.83%▲0.1
Public24.89%24.75%▼0.124.2%▼0.623.79%▼0.423.81%▲0.023.51%▼0.323.3%▼0.223.23%▼0.1

Financial Statements

MetricSep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025
Sales215202195203204208205227230231
Expenses176165161167166174178195195195
Operating Profit39363436393427323636
OPM %18%18%18%18%19%16%13%14%16%16%
Net Profit2322202122198121516
EPS ₹2.392.2222.082.171.930.791.21.491.55

AI Insights

Revenue Trend

TTM revenue at ₹893Cr, up 8.9% YoY. OPM at 15%.

Debt Position

Borrowings at ₹369Cr. Debt-to-equity ratio: 0.60x. Moderate leverage.

Capex Cycle

CWIP at ₹24Cr (5% of fixed assets). Moderate ongoing capital expenditure.

Institutional Flow

DIIs: 3.83% (+2.67pp change). FIIs: 0.42% (-0.28pp change). Promoters hold 72.5%.

Margin & Efficiency

ROCE declining from 17% (Mar 2014) to 13% (Mar 2025). Working capital days: 93.

Valuation

PE 54.6x with 13.2% ROCE. Price is 339% above book value of ₹62.7. Dividend yield: 0.04%.

Recent Announcements